How many insider trades does FilingIQ track for BCRX?

FilingIQ tracks 634 Form 4 insider transactions for BCRX (BIOCRYST PHARMACEUTICALS INC), covering filings from Jan 8, 2015 onwards. 16 of those were filed in the last 90 days.

Are BCRX insiders net buyers or net sellers?

Across the full Form 4 history for BCRX, 34 transactions (5%) were open-market purchases and 137 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BCRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BCRX in?

BIOCRYST PHARMACEUTICALS INC (BCRX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.89B.

BCRX insider trading

NasdaqGS Healthcare

BIOCRYST PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

634

Last 90 days

Buys / sells

5% / 22%

Market cap

$1.89B

About BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Company website: www.biocryst.com

BCRX insider activity at a glance

FilingIQ has scored 634 insider transactions for BCRX since Jan 8, 2015. The most recent filing in our index is dated Apr 6, 2026.

Across the full history, 34 open-market purchases and 137 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BCRX insider trades is 58.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BCRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for BCRX?: FilingIQ tracks 634 Form 4 insider transactions for BCRX (BIOCRYST PHARMACEUTICALS INC), covering filings from Jan 8, 2015 onwards. 16 of those were filed in the last 90 days.
Are BCRX insiders net buyers or net sellers?: Across the full Form 4 history for BCRX, 34 transactions (5%) were open-market purchases and 137 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BCRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BCRX in?: BIOCRYST PHARMACEUTICALS INC (BCRX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.89B.

Methodology & sources

Every BCRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.